Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(Nasdaq: MIRM) today announced that on 10, 2025, the Compensation Committee of Mirum’s Board of Directors granted inducement ...
Viking Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its ...
Viking Therapeutics, Inc.: Viking Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update
Conference call scheduled for 4:30 p.m. ET today Initiation of Phase 3 Studies for Subcutaneous VK2735 for Obesity Planned for 2Q25 Phase 2 VENTURE-Oral Dosing Trial ...
Yahoo Finance5d
Mirum Pharmaceuticals, Inc. (MIRM)
After hours: February 7 at 4:02:14 PM EST Loading Chart for MIRM ...